Retension Pharmaceuticals(RTSN)
MCLEAN, VAPharmaceutical
Focus: Retension Pharmaceuticals is a public pharmaceutical company headquartered in McLean, VA, focused on PDE5 inhibitor development for neurological indications. The company is advancing a small pipeline of Phase 2 programs targeting hypertension and uncontrolled hypertension.
Profile data last refreshed 53m ago · AI intelligence enriched 3w ago
Funding Stage
PUBLIC
Open Jobs
0
About Retension Pharmaceuticals
AI assessmentNot HiringNo open roles listed right now. Follow Retension Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Retension Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Early-stage
3 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
RTN-001
Uncontrolled HypertensionClinical Trials (1)
NCT07142356A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension
Phase 2Help build intelligence for Retension Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.